Evidence map›Paper›PMID 41849725›Full record

Observational studyJCO clinical cancer informatics2026

Leveraging Digital Technology and Artificial Intelligence to Describe the Real-World Belgian Chronic Lymphocytic Leukemia Patient Population: The BE-CLLEAR Study.

Matthias Vanderkerken, Koen Van Eygen, Veerle Galle, Annelies Verbiest, Ann Janssens, Imke Masuy, Kristof Theys, Tine Cuppens, Katoo Muylle, Ann De Becker

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in JCO clinical cancer informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Matthias VanderkerkenDivision of Hematology and Center for Cell Therapy & Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium.ORCID 0000-0002-0785-5904
Koen Van EygenDepartment of Hematology, AZ Groeninge, Kortrijk, Belgium.ORCID 0000-0001-8285-906X
Veerle GalleDepartment of Hematology, AZ Maria Middelares, Ghent, Belgium.
Annelies VerbiestDepartment of Oncology, Multidisciplinary Oncological Center Antwerp, Antwerp University Hospital, Edegem, Belgium.ORCID 0000-0001-9024-863X
Ann JanssensDepartment of Hematology, UZ Leuven Gasthuisberg, Leuven, Belgium.
Imke MasuyLynxCare Clinical Informatics, Leuven, Belgium.
Kristof TheysKintiga Ltd, Ghent, Belgium.ORCID 0000-0003-0242-7000
Tine CuppensAstraZeneca Belux, Groot-Bijgaarden, Belgium.
Katoo MuylleAstraZeneca Belux, Groot-Bijgaarden, Belgium.ORCID 0000-0003-1117-6709
Ann De BeckerDepartment of Hematology, UZ Brussel, Jette, Belgium.ORCID 0000-0003-0947-8708

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeChronic lymphocytic leukemia (CLL) treatment paradigms have evolved significantly, yet real-world evidence (RWE) on guideline implementation and patient characteristics remains limited. MATERIALS AND

methodsThis multicenter retrospective study leveraged artificial intelligence (AI) to analyze structured and unstructured data from four Belgian hospitals (January 1, 2018-October 31, 2021). Structured data including diagnosis codes, laboratory results, treatment records, and national registries were standardized using the Observational Medical Outcomes Partnership (OMOP) Common Data Model. Unstructured clinical notes and reports were processed using a transformer-based natural language processing (NLP) pipeline. We examined clinical characteristics, diagnostic testing, and treatment patterns among patients with newly diagnosed CLL.

resultsOf 22 variable groups analyzed, 50.0% was derived from structured data only, 36.4% from unstructured data only (NLP-extracted), and 13.6% from mixed sources. Five hundred eighty-six patients with CLL were identified, with a median age of 74 years. One hundred seventy-four patients (29.7%) initiated first-line (1L) treatment, and 41 progressed to second-line treatment. Of 1L treated patients, 68.4% had at least one prespecified comorbidity, including 12.1% with significant cardiovascular disease.

conclusionThis AI-augmented study demonstrates the feasibility and scalability of combining NLP-derived insights with OMOP-standardized structured data to generate reproducible RWE in hematology. Our results highlight an elderly CLL population with significant comorbidities and a shift toward targeted therapies. While treatment patterns aligned with guidelines, data quality depended on source documentation accessibility. Improved integration of molecular testing into electronic health records is essential for enhancing clinical decision making, patient outcomes, and future research.

Indexed as

Artificial IntelligenceLeukemia, Lymphocytic, Chronic, B-CellAgedAged, 80 and overBelgiumDigital HealthElectronic Health RecordsFemaleHumansMaleMiddle AgedNatural Language ProcessingRetrospective Studies

Identifiers

PMID41849725
PMCPMC13003938

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.